Navigation Links
Poster & Abstract Entitled 1H-MRS & FDG-PET Studies in the SOD1 G93A - the Use of Stabilized Peptides as a Rationale for Future Treatment in ALS Presented During Annual Northeast ALS Consortium Meeting
Date:10/30/2013

CLEARWATER, Florida, October 30, 2013 /PRNewswire/ --

Daval International, the emerging life sciences company focused on the development of novel treatments for serious unmet medical needs, presented a poster at the 12th Annual Meeting of the North East ALS (NEALS) Consortium which took place 3rd-4th October 2013, at the Sandpearl Resort, Clearwater Beach, FL, USA. The poster was entitled "1H-MRS & FDG-PET studies in the SOD1 G93A - the use of stabilized peptides as a rationale for future treatment in ALS" and was co-authored by scientists and researchers from Daval and Charles River Discovery Research Services, Finland.

The North East ALS Consortium is an alliance of medical institutions that are equipped to perform clinical trials in Amyotrophic Lateral Sclerosis (ALS) and motor neuron diseases. The Annual NEALS Meeting serves as an opportunity for NEALS researchers to liaise with leading ALS and motor neuron disease scientists, government sponsors, academic partners and pharmaceutical companies in order to discuss potential treatments, to review current research activities and to share scientific updates.  

The objectives of the studies were to determine whether targeting of the hypothalmo-pituitary-adrenal axis at a specific site using AIMSPRO®, the novel multi-protein-peptide conjugate complex, currently in clinical development, could elicit multiple measurable efficacy traits in the G93A SOD1 murine model. The SOD-1 model is the most studied ALS mouse model and the results showed clinical efficacy, associated changes in brainstem 1H-MRS metabolites and appeared to target glutamate/glutamine availability and in a separate study rescued the G93A SOD1 brain from hypometabolism.

Professor Syed Haq, Daval's Chief Clinical & Scientific Officer and one of the co-authors, presented the poster in Florida and commented, "These results are extremely encouraging and supportive of other studies that have been undertaken pre-clinically as well as in double-blind, placebo-controlled clinical trials in humans. The Implications and findings has led to further work to elucidate the potential targets in ALS that may have future therapeutic implications in the treatment of patients diagnosed with ALS where glutamate exocitotoxicity and hypometabolism of the brain have been defined as potential pathogenic mechanisms in the evolution of the disease".

The poster will be available for download at the Daval International website shortly, as soon as the organisers permission has been obtained.

Notes to Editors

About AIMSPRO®

AIMSPRO® is a proprietary, purified, protein-multi-peptide conjugate complex being developed as a novel, first-in-class biological treatment for a number of neurological and autoimmune diseases where regulation and stabilisation of the immune system is required. The therapeutic has a unique mechanism of action that supports its broad potential application in neuro-degenerative diseases. AIMSPRO has been granted a Specials License by the UK's MHRA and has been granted Orphan Drug Designation for ALS by the Food & Drug Administration (FDA) in the United States.

About Daval International Limited

DAVAL INTERNATIONAL LIMITED is an emerging life sciences company focused on the development and delivery of novel and distinctive treatments for serious unmet medical needs through a combination of innovation, dedication, entrepreneurship, skilled science and partnership. From its inception in 2000, the founder and management team of Daval have had a vision of bringing effective treatments that noticeably improves the quality of life of patients suffering from the most serious debilitating neuro-degenerative, inflammatory and autoimmune diseases and to offer a choice over and above some of the disease modifying treatments available currently.

For further information please contact:

Edward Jensen +1-484-716-9305 or +44(0)7775-793513 edward.jensen@davalinternational.com

Graham Ralph  +44-(0)845-130-3014 graham.ralph@davalinternational.com


'/>"/>
SOURCE Daval International
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting
2. Signature Therapeutics, Inc., Presents Four Scientific Posters Today at PAINWeek 2013 Meeting
3. Asmacure to Present Four Posters on Novel Pulmonary Development Compound ASM-024 at American Thoracic Society 2013 International Conference
4. MedImmune To Present Seven Posters On Influenza, Respiratory Syncytial Virus At The Annual Pediatric Academic Societies Meeting
5. Data Related to Chimerixs Antiviral CMX001 to be Presented in Three Poster Sessions at the BMT Tandem Meetings
6. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
9. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
10. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
11. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... an agreement to acquire a majority ownership interest in ... equipment in Brazil . ... Blumenau, Brazil, Dental Cremer is the dental distribution business of ...
(Date:2/5/2016)... 4, 2016 France , ... , UK, and Israel ). It includes a 10-year ... 3 GD, segmented by age and sex in these markets. GD epidemiology ... Report is in-depth, high quality, transparent and market-driven, providing expert analysis of ... Germany , Italy , ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
Breaking Medicine Technology:
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... Looking for ... may be at the tips of your toes. Foot massage, whether administered by a ... pure comfort and relaxation. The American Board of Multiple Specialties in Podiatry ...
(Date:2/5/2016)... ... February 05, 2016 , ... In ... across the country gathered at the La Valencia Hotel in San Diego, California ... Chicago was named the year’s most outstanding franchise, walking away with the coveted ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point Consulting, a leading ... Software & Services for HIT Implementation Support & Staffing report with an outstanding ... performance by healthcare executives, managers and clinicians representing over 4,500 hospitals and 2,500 ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Colorize ... on one drop zone to the next using Colorize's dynamic moving camera. Colorize is ... This package includes a 3D slideshow environment with 1 to 5 focus points per ...
Breaking Medicine News(10 mins):